A small pilot trial at the University of Missouri found that a low daily dose of rapamycin, a decades-old drug normally used to prevent organ-transplant rejection, improved blood flow to the brain in middle-aged adults carrying the APOE4 gene variant — the strongest common genetic risk factor for late-onset Alzheimer's disease.
The study, led by Ai-Ling Lin at the University of Missouri School of Medicine and published in the Journal of Cerebral Blood Flow & Metabolism, gave healthy adults ages 45 to 65 — some carrying APOE4, some not — a low daily dose of rapamycin for four weeks. None of the participants had Alzheimer's symptoms. Brain blood flow improved meaningfully in the APOE4 carriers; it did not improve in participants without the variant, suggesting the drug's effect is specific to people already carrying higher genetic risk.
Why blood flow, and why women
Women carrying APOE4 showed the largest gains in cerebral blood flow of any group in the trial — notable, researchers said, because women make up nearly two-thirds of people living with Alzheimer's disease. Reduced blood flow in parts of the brain can show up years before memory symptoms appear, which is why Lin's team is treating it as a possible early warning sign worth intervening on, rather than waiting for cognitive decline to start.
The result builds on Lin's earlier mouse experiments, which found that rapamycin slowed markers of brain aging and increased blood flow in animals engineered to carry the APOE4 variant. Lin, who holds appointments in the School of Medicine and the College of Arts and Science and works out of the university's Roy Blunt NextGen Precision Health building, said the finding points toward a more targeted way of using an old drug.
Alzheimer's tends to happen more in older people, especially for those with APOE4. This research is an example of precision medicine, as we work to identify who can benefit from this drug the most.
Ai-Ling Lin, University of Missouri School of Medicine
The trial does not show whether rapamycin prevents Alzheimer's or preserves memory over the long run — it measured blood flow and related biological markers over just four weeks, in a small group of cognitively healthy volunteers. Lin's team says the next step is to track whether the blood-flow gains translate into any lasting cognitive benefit, and whether the effect holds up in a larger trial. Rapamycin's established side effects, including suppressed immune response at higher doses, mean any future use for brain aging would need its own safety and dosing studies rather than borrowing directly from its transplant-medicine playbook.
